Success Metrics

Clinical Success Rate
87.5%

Based on 14 completed trials

Completion Rate
88%(14/16)
Active Trials
11(31%)
Results Posted
29%(4 trials)
Terminated
2(6%)

Phase Distribution

Ph early_phase_1
1
3%
Ph phase_3
4
11%
Ph not_applicable
19
54%
Ph phase_1
2
6%

Phase Distribution

3

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution26 total trials
Early Phase 1First-in-human
1(3.8%)
Phase 1Safety & dosage
2(7.7%)
Phase 3Large-scale testing
4(15.4%)
N/ANon-phased studies
19(73.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

77.8%

14 of 18 finished

Non-Completion Rate

22.2%

4 ended early

Currently Active

11

trials recruiting

Total Trials

35

all time

Status Distribution
Active(12)
Completed(14)
Terminated(4)
Other(5)

Detailed Status

Completed14
Active, not recruiting6
unknown5
Recruiting5
Terminated2
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
35
Active
11
Success Rate
87.5%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (3.8%)
Phase 12 (7.7%)
Phase 34 (15.4%)
N/A19 (73.1%)

Trials by Status

completed1440%
enrolling_by_invitation13%
terminated26%
unknown514%
withdrawn26%
active_not_recruiting617%
recruiting514%

Recent Activity

Clinical Trials (35)

Showing 20 of 35 trialsScroll for more
NCT06611540Not Applicable

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)

Active Not Recruiting
NCT06611553Not Applicable

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02)

Active Not Recruiting
NCT06498661Not Applicable

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)

Active Not Recruiting
NCT07480902Not Applicable

Comparison Between Liquid-Based Cytology And Molecular Screening For Detecting Precursor Lesions and Cervical Cancer

Recruiting
NCT07211204Not Applicable

Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population

Withdrawn
NCT06147388

Regression of Cervical Precancerous Lesions and Associated Risk Factors

Recruiting
NCT07281430Not Applicable

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)

Recruiting
NCT05074264Not Applicable

Screening Algorithms for Cervical and Anal High-Grade Squamous Intraepithelial Lesions in People With HIV in Mexico and Puerto Rico

Active Not Recruiting
NCT06165614Phase 1

Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya

Completed
NCT02956031

Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women.

Recruiting
NCT05231993Not Applicable

Clinical Triage and Treatment of Atypical Glandular Cells (AGC) Detected in Screening

Enrolling By Invitation
NCT05000957Not Applicable

Pelvic Organs Prolapse Treatment Using Neodymium Laser

Active Not Recruiting
NCT06644248

AI Model for Cervical Cancer Detection From Colposcopy Images

Recruiting
NCT04794660Phase 3

The Study for the "Cervical Cancer Screening and Treatment Algorithms Study Using HPV Testing in Africa"

Active Not Recruiting
NCT02634190

Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HC2® Test Using LBC ThinPrep® Specimens

Completed
NCT02420665Early Phase 1

Use of High-Resolution Microendoscopy (HRME) in Patients With Cervical Dysplasia

Completed
NCT04783649

Clinical Validation of Cervical Cancer Screening Methods

Unknown
NCT02267876

Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical Specimens

Completed
NCT04369339Not Applicable

Colposcopy Findings Among Women With High Risk HPV Other Than HPV 16/18 and Normal Cytology

Completed
NCT04340011

Colposcopy Education Using Operant Learning

Unknown

Drug Details

Intervention Type
PROCEDURE
Total Trials
35